DEA mandates reduction in opioid manufacturing for 2018 – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
DEA’s finalized annual aggregate production quotas (APQs) for 2018 mandate a 20% reduction in the amount of opiate and opioid medication—including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine, and fentanyl—that may be manufactured in 2018. Quotas are aimed at preventing a diversion while simultaneously satisfying annual needs.
APQs establish the total amount of opioids and other controlled substances necessary to meet the estimated medical, scientific, research, industrial, and export needs for 2018 and to maintain adequate reserve stocks. DEA says 2018’s cuts are a response to reduced demand.
Quotas may be appealed at any time during the year on the basis of increased sales or exports, new manufacturers entering the market, new product development, or product recalls.
Critics of DEA’s decision have expressed concerns that the reduced quota could lead to drug shortages and negatively affect pain management patients’ access to treatment.